#1 Clinical Trials Search in Europe

Tobevibart

This article explores the ongoing clinical trials investigating the use of Tobevibart (VIR-3434) in treating chronic hepatitis B (HBV) and hepatitis D (HDV) infections. These studies aim to assess the safety, efficacy, and tolerability of Tobevibart, often in combination with other therapies, to potentially improve outcomes for patients with these challenging viral liver diseases.

Table of Contents

What is TOBEVIBART?

TOBEVIBART is a new investigational drug being developed to treat chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. It is also known by its product name VIR-3434[1]. TOBEVIBART is a human immunoglobulin G1 (IgG1) monoclonal antibody, which means it’s a type of protein designed to target specific parts of the viruses that cause hepatitis B and D[2].

How does TOBEVIBART work?

As a monoclonal antibody, TOBEVIBART is designed to specifically target and bind to certain parts of the hepatitis B and D viruses. While the exact mechanism is still being studied, it’s believed that by binding to these viruses, TOBEVIBART may help prevent them from infecting liver cells and replicating. This could potentially lead to a reduction in the amount of virus in the body and help the immune system better control the infection[1][2].

What conditions does TOBEVIBART treat?

TOBEVIBART is being developed to treat two main conditions:

  1. Chronic Hepatitis B Virus (HBV) Infection: This is a long-lasting liver infection caused by the hepatitis B virus. It can lead to serious liver problems, including cirrhosis and liver cancer if left untreated[2][3].
  2. Chronic Hepatitis D Virus (HDV) Infection: This is considered the most severe form of viral hepatitis. It only occurs in people who are also infected with hepatitis B. HDV can cause the liver disease to progress more quickly and increase the risk of liver-related complications[1].

Clinical Trials and Research

TOBEVIBART is currently being studied in several clinical trials to evaluate its safety and effectiveness. These trials include:

  • SOLSTICE Study: This is a Phase 2 study evaluating the efficacy, safety, and tolerability of TOBEVIBART (VIR-3434) in combination with another drug called VIR-2218 in patients with chronic hepatitis D infection[1].
  • PREVAIL Study: This is a platform study evaluating multiple investigational therapies, including TOBEVIBART, in patients with chronic hepatitis B infection[2].
  • VIR-2218-1006 Study: This Phase 2 study is evaluating the safety, tolerability, and efficacy of regimens containing TOBEVIBART (VIR-3434) and other drugs in subjects with chronic hepatitis B virus infection[3].

Potential Benefits

The ongoing clinical trials are investigating several potential benefits of TOBEVIBART, including:

  • Reduction in hepatitis B surface antigen (HBsAg) levels[2][3]
  • Suppression of hepatitis B virus DNA[2][3]
  • Potential for functional cure of hepatitis B (defined as undetectable HBsAg and sustained suppression of HBV DNA)[3]
  • Improvement in liver health markers[1]

Safety and Side Effects

As TOBEVIBART is still in clinical trials, its full safety profile is not yet known. The ongoing studies are closely monitoring for any adverse events or side effects. Common side effects of monoclonal antibodies can include injection site reactions, fatigue, and potential allergic reactions. However, it’s important to note that each person may react differently to the medication[1][2][3].

Administration

TOBEVIBART is administered as a subcutaneous injection, which means it’s injected under the skin. The dosing schedule and duration of treatment are still being determined through the clinical trials. In the studies, doses up to 300 mg have been used, with treatment periods lasting up to 48 weeks[1][2][3].

Conclusion

TOBEVIBART (VIR-3434) represents a promising new approach in the treatment of chronic hepatitis B and D infections. While still in the investigational stage, it offers hope for improved outcomes for patients living with these challenging liver conditions. As research continues, more information about its effectiveness and safety will become available. Patients interested in learning more about TOBEVIBART should consult with their healthcare providers and consider the possibility of participating in clinical trials if appropriate.

Aspect Details
Drug Name Tobevibart (VIR-3434)
Drug Type Human immunoglobulin G1 (IgG1) monoclonal antibody
Administration Subcutaneous injection
Target Conditions Chronic Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) infections
Trial Phases Phase 2
Key Objectives Evaluate safety, tolerability, and efficacy in reducing viral levels and achieving functional cure
Primary Endpoints HBsAg loss, HBV DNA suppression, ALT normalization, adverse events
Combination Therapies Often studied with other antivirals or immunomodulators (e.g., VIR-2218, peginterferon alfa-2a)
Duration of Treatment Varies by trial, up to 48 weeks in some studies
Follow-up Period Up to 24 weeks post-treatment in some trials

FAQ

  • What is Tobevibart? Tobevibart, also known as VIR-3434, is an investigational human immunoglobulin G1 (IgG1) monoclonal antibody being studied for the treatment of chronic hepatitis B and D infections.
  • What are the main goals of the clinical trials involving Tobevibart? The main goals are to evaluate the safety, tolerability, and efficacy of Tobevibart, often in combination with other therapies, in reducing viral levels, normalizing liver enzymes, and potentially achieving functional cure in patients with chronic hepatitis B or D infections.
  • How is Tobevibart administered in these trials? Tobevibart is administered as a subcutaneous injection, with dosing and frequency varying depending on the specific trial protocol.
  • What are some of the key outcomes being measured in these trials? Key outcomes include changes in hepatitis B surface antigen (HBsAg) levels, hepatitis B or D virus DNA levels, liver enzyme normalization, and the proportion of patients achieving functional cure or viral suppression.
  • Are there any specific safety concerns being monitored in these trials? While specific safety concerns are not detailed, the trials are closely monitoring for treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). They are also assessing the development of anti-drug antibodies to Tobevibart.

Ongoing Clinical Trials on Tobevibart

  • Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Italy The Netherlands +2

  • Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Italy Romania Spain

  • Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Romania

  • Study on the Effects of VIR-2218 and VIR-3434 for Patients with Chronic Hepatitis D Infection

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Germany Italy The Netherlands Romania

  • Study on the Safety and Effectiveness of VIR-2218, VIR-3434, and Peginterferon Alfa-2a for Patients with Chronic Hepatitis B

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany Romania

  • Study on the Effects of Peginterferon Alfa-2a, Tobevibart, and Elebsiran in Patients with Chronic Hepatitis B Infection

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Romania

Glossary

  • Hepatitis B virus (HBV): A viral infection that attacks the liver and can cause both acute and chronic disease. It is transmitted through contact with blood or other body fluids of an infected person.
  • Hepatitis D virus (HDV): A virus that requires the presence of hepatitis B virus to replicate and can lead to more severe liver disease in people already infected with HBV.
  • HBsAg: Hepatitis B surface antigen, a protein on the surface of the hepatitis B virus. Its presence in the blood indicates current hepatitis B infection.
  • Functional cure: In hepatitis B, this typically refers to the loss of hepatitis B surface antigen (HBsAg) and sustained suppression of HBV DNA, even after stopping all treatments.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In this case, Tobevibart is a monoclonal antibody designed to target hepatitis B virus.
  • Subcutaneous injection: A method of administering medication by injecting it into the tissue layer between the skin and the muscle.
  • ALT normalization: The return of alanine aminotransferase (ALT) liver enzyme levels to within normal range, often indicating reduced liver inflammation or damage.
  • NRTI: Nucleos(t)ide reverse transcriptase inhibitor, a class of antiviral medications commonly used to treat chronic hepatitis B infections.
  • Anti-HBs: Antibodies to the hepatitis B surface antigen, which typically indicate recovery from HBV infection or successful vaccination.
  • HBeAg: Hepatitis B e antigen, a viral protein that indicates active viral replication in chronic hepatitis B infection.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-vir-2218-and-vir-3434-for-patients-with-chronic-hepatitis-d-infection/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-peginterferon-alfa-2a-tobevibart-and-elebsiran-in-patients-with-chronic-hepatitis-b-infection/
  3. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vir-2218-vir-3434-and-peginterferon-alfa-2a-for-patients-with-chronic-hepatitis-b/